

Universal Biosensors, Inc.
ARBN 121 559 993

1 Corporate Avenue
Rowville Victoria 3178
Australia

Telephone +61 3 9213 9000
Facsimile +61 3 9213 9099
Email info@universalbiosensors.com
www.universalbiosensors.com



ASX Announcement
17 July 2018

ASX: UBI

EXPIRY OF UNLISTED OPTIONS

The Company wishes to advise of the following changes in its securities:

- Lapsing of the following options without exercise:
 - 60,000 Options (A\$0.94, 28 June 2019) – equivalent to 60,000 CDIs
 - 160,000 Options (A\$1.72, 9 November 2019) – equivalent to 160,000 CDIs
 - 15,000 Options (A\$0.89, 17 November 2018) – equivalent to 15,000 CDIs
 - 15,000 Options (A\$1.09, 12 November 2019) – equivalent to 15,000 CDIs
 - 15,000 Options (A\$0.49, 11 December 2020) – equivalent to 15,000 CDIs
 - 15,000 Options (A\$0.23, 29 January 2022) – equivalent to 15,000 CDIs
 - 13,332 Options (A\$0.45, 13 December 2022) – equivalent to 13,332 CDIs
 - 1,298,000 Options (A\$0.50, 20 April 2023) – equivalent to 1,298,000 CDIs
 - 126,000 Options (A\$0.50, 27 February 2024) – equivalent to 126,000 CDIs

The capital structure of the Company following the release of the unquoted securities is as follows:

Quoted Securities

176,750,217 Ordinary Fully Paid Shares (equivalent to 176,750,217 CDIs)

Unquoted Securities

Number	Instrument	Exercise Price	Expiry Date	CDI Equivalent
216,444	Restricted Shares	N/A	N/A	216,444
102,000	Employee Options	\$0.70	19-Aug-18	102,000
8,000	Employee Options	\$0.50	16-Feb-19	8,000
16,667	Employee Options	\$0.00	14-May-19	16,667
283,334	Employee Options	\$0.00	28-Jun-19	283,334
428,667	Employee Options	\$0.94	28-Jun-19	428,667
725,000	Employee Options	\$1.72	9-Nov-19	725,000
66,000	Employee Options	\$1.00	21-Sep-18	66,000
152,500	Employee Options	\$0.89	17-Nov-18	152,500
75,000	Employee Options	\$0.00	17-Nov-18	75,000
20,000	Employee Options	\$0.75	12-Mar-19	20,000
12,000	Employee Options	\$0.73	13-Sep-19	12,000
175,000	Employee Options	\$1.09	12-Nov-19	175,000
75,000	Employee Options	\$0.00	12-Nov-19	75,000
24,000	Employee Options	\$0.79	11-Mar-20	24,000
30,000	Employee Options	\$0.71	12-Nov-19	30,000



Universal Biosensors

172,500	Employee Options	\$0.49	11-Dec-20	172,500
120,000	Employee Options	\$0.00	11-Dec-20	120,000
80,000	Employee Options	\$0.17	13-Aug-21	80,000
215,000	Employee Options	\$0.23	29-Jan-22	215,000
120,000	Employee Options	\$0.00	29-Jan-22	120,000
257,498	Employee Options	\$0.45	13-Dec-22	257,498
5,725,000	Employee Options	\$0.50	20-Apr-23	5,725,000
173,167	Employee Options	\$0.33	27-Dec-23	173,167
841,050	Employee Options	\$0.50	27-Feb-24	841,050
1,600,000	Employee Options	\$0.50	23-Oct-22	1,600,000
2,700,000	Employee Options	\$0.60	23-Oct-22	2,700,000
3,300,000	Employee Options	\$0.80	23-Oct-22	3,300,000
4,500,000	Warrants	\$1.00	19-Dec-20	4,500,000

-Ends-

Enquiries:
Mr. Satesh Balak: 03 9213 9000

About Universal Biosensors

For additional information regarding Universal Biosensors, refer to: <http://www.universalbiosensors.com/>. Universal Biosensors is a specialist medical diagnostics company, founded in 2001, that is focused on the development, manufacture and commercialisation of a range of in vitro diagnostic tests for point-of-care use. These tests capitalise on a technology platform which uses a novel electrochemical cell that can be adapted for multiple analytes and provide for enhanced measurements in whole blood.

Forward-Looking Statements

The statements contained in this release that are not purely historical are forward-looking statements within the meaning of the US Securities Exchange Act of 1934. Forward-looking statements in this release include statements regarding our expectations, beliefs, hopes, intentions or strategies. All forward-looking statements included in this release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. Our actual results could differ materially from our current expectations. We cannot assure you when, if at all, the proposals outlined in this release will occur, and the terms of any such proposal are subject to change. Factors that could cause or contribute to such differences include, but are not limited to, factors and risks disclosed from time to time in reports filed with the SEC.